CARLSBAD, Calif., Feb 10, 2004 (BUSINESS WIRE) -- Invitrogen Corp. (Nasdaq: IVGN) announced today that it has completed its acquisition of BioReliance Corp. Invitrogen acquired BioReliance through a cash tender offer for $48.00 a share, and a subsequent merger of a wholly-owned subsidiary with and into BioReliance. BioReliance shares have been delisted from Nasdaq, and ceased trading at the close of business on Friday, February 6, 2004.
Invitrogen Corp. (Nasdaq: IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, Calif. and conducts business in more than 70 countries around the world. The company globally employs approximately 3,000 scientists and other professionals. For more information about Invitrogen, visit the company's Web site at www.invitrogen.com.
SOURCE: Invitrogen Corp.
Invitrogen Corp., Carlsbad
C. Eric Windzer, CFO, 760-603-7211